ICON : Integrated Community Oncology Network
Home Page FOA FROG ICON : Integrated Community Oncology Network
Practice Locations
Physicians
Research and Clinical Trials
PET/CT Center
 
 

ICON Clinical Trials

Last Updated: 8/20/2008

Choose Area of Study
Bladder Brain Breast Colon
Gyn Head & Neck Leukemia Lung
Lung-PET Lymphoma Melanoma MGUS
Multiple Myeloma Myelodysplastic Syndrome Prostate Renal
Esophagus ITP Rectal Unknown Primary


Bladder
SPONSOR/CROSTUDYSTATUS

BACK TO TOP
Brain
SPONSOR/CROSTUDYSTATUS
RTOG 0525

Phase III Glioblastoma Multiforme Study of Conventional Adjuvant Temodar versus Dose Intensive Temodar

OPEN
RTOG 0320

A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone vs with Temozolomide or Erlotinib in Patients with NSCLC and 1-3 Brian Metastases

OPEN
RTOG 0627Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma MultiformeOPEN
NCCTG N0574Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral MetastasesOPEN
RTOG 0614A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole Brain RadiotherapyOPEN

BACK TO TOP
Breast
SPONSOR/CROSTUDYSTATUS
B-39/RTOG 0413A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, II Breast Cancer.OPEN
RTOG 0517Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast and Prostate.OPEN
VER 06Clinical Correlation of Circulating Tumor Cell Count and Molecular Imaging by Fusion PET/CT Scanning in Metastatic Breast Cancer Patients.OPEN
BRE 97

A Phase IIb, Randomized, Multicenter, Noncomparatve Pilot Study of the Safety and Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab +/- Trastuzumab for the Adjuvant Treatment of Patients with Node-Positive and High-Risk Node Negative Breast Cancer

*Note - Only the Her 2 positive arm is open to accrual.

OPEN
ECOG PACCT-1/ TAILORxProgram for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx TrialOPEN
NSABP B-42A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen followed by an AI in Prolonging Disease Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast CancerOPEN
NCCTG ALLTOA Randomized, Open-Labe, Multi-Center Phase III Study Comparing the Activity of Lapatinb Alone versus Trastuzumab Alone versus Lapatinib Followed by Trastuzumab in the Adjuvant Treatment of Patients with Erb2 Over-expressing and/or Amplified Breast CancerOPEN
BRE 86A Phase II Trial of Open Label Bevacizumab Administered with Anastrozole or Fulvestrant as First Line Therapy in Postmenopausal Hormone Receptor Positive Metastatic Breast CancerOPEN
Docet_L_00712A Pilot, Phase II, Multicenter, Open-Label, Prospective Study of Docetaxel and Bevacizumab +/- Trastuzumab in the First Line Treatment of Patients with Metastatic Breast CancerOPEN
CIRG(BETH)

A Multi-centered Phase III Randomized Trial of Adjuvant Therapy for Patients with Her2 Positive Node Positive of High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

 

 

OPEN
VIRGO (AVF4349g)An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast CancerOPEN

BACK TO TOP
Colon
SPONSOR/CROSTUDYSTATUS
N0147A Randomized, Phase III Trial of Oxaliplatin (OXAL) Plus 5-Flourouracil (5-FU)/Leucovorin (CF) +/- Cetuximab after Curative Resection for Patients with Stage III Colon CancerOPEN
ECOG E5202A Randomized, Phase III Study Comparing 5FU, Leucovorin, Oxaliplatin versus 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular MarkersOPEN
ION 07-014

A Randomized, Phase 2B Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX as First-Line Treatment in Patients with Metastatic Colorectal Cancer

OPEN
AVF3991n

An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced of Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent of Metastatic Breast Cancer

*Note - only 2nd line mCRC and NSCLC open

OPEN
SPIRITT 20060141A Multi-Center Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab of Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer  SPIRITT (Second-Line Panitumumab-IRInotecan Treatment Trial) OPEN
SP 04721A Fixed Sequence, Open-Label Study to Determine the Activity of SCH 717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed of Recurrent Colorectal Cancer OPEN

BACK TO TOP
Gyn
SPONSOR/CROSTUDYSTATUS
RTOG 0417Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical CarcinomaOPEN

BACK TO TOP
Head & Neck
SPONSOR/CROSTUDYSTATUS
RTOG 0522A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab Followed by Surgery for Selected Patients for Stage III and IV Head and Neck CarcinomasOPEN
RTOG 0615A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) of Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal CancerOPEN

BACK TO TOP
Leukemia
SPONSOR/CROSTUDYSTATUS
DMS 0337A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic SyndromeOPEN

BACK TO TOP
Lung
SPONSOR/CROSTUDYSTATUS
RTOG 0320A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone vs with Temozolomide or Erlotinib in Patients with NSCLC and 1-3 Brian MetastasesOPEN
LUN 1105A Phase II Trial of Weekly Topotecan in the First Line Treatment of Elderly or Poor Performance Patient with NSCLCOPEN
RTOG 0517Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastasis from Lung, Breast, and ProstateOPEN
RTOG 0538Phase III Comparison of Thoracic Radiotherapy Regimens with Limited SCLC also Receiving Cisplatin and EtoposideOPEN
ION 08-014A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLS)OPEN
ION 07-021A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line ChemotherapyOPEN
LUN 149A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-Positive TumorsOPEN
RTOG 0617A Randomized Phase III Comparison of Standard Dose (60 Gy) versus High Dose (74 Gy) Confromal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non Small Cell Lung CancerOPEN
AVF 3991nAn Observational Study of Avastin® (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced of Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent of Metastatic Breast CancerOPEN
ION 06-004 Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination with Paclitaxel and Carboplatin in Patients with Stage IIIB/IV Non-Small Cell Lung CancerOPEN
ION-08-014/GEM 017A Phase I followed by a Randomized Phase II Study of Carboplatin and Etoposide with or without Obatoclax administered every 3 weeks to patients with Extensive -Stage Small Cell Lung CancerOPEN

BACK TO TOP
Lung-PET
SPONSOR/CROSTUDYSTATUS
RTOG 0235Positron Emission Tomography Pre and Post-Treatment Assessment for Locally Advanced Non-Small Cell Lung CarcinomaOPEN

BACK TO TOP
Lymphoma
SPONSOR/CROSTUDYSTATUS
RTOG 0227A Phase I/II Study of Pre-Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and Post-Irradiation Temozolomide for Primary Central Nervous System LymphomaOPEN
LYM 54An Open-Label ,Randomized, Phase II Study of R-CHOP plus Enzastaurin Pversus R-CHOP in the First Line Treatment of patients with Intermediate and High Risk Diffuse Large B Cell LymphomaOPEN

BACK TO TOP
Melanoma
SPONSOR/CROSTUDYSTATUS
ION 07-020Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant MelanomaOPEN

BACK TO TOP
MGUS
SPONSOR/CROSTUDYSTATUS
ZOMGUS 001Phase I/II Trial of Zometa in Patients with Monoclonal Gammopathy of Undertermined Significance (MGUS)OPEN

BACK TO TOP
Multiple Myeloma
SPONSOR/CROSTUDYSTATUS
ZMARKBone Marker Directed Dosing of ZOMETA® (zoledronic acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple MyelomaOPEN

BACK TO TOP
Myelodysplastic Syndrome
SPONSOR/CROSTUDYSTATUS
DMS-0337A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic SyndromeOPEN
Alexion P06-001

Examination of PNH, by Level Of CD59 on Red and white blood cells, in bone marrow failure syndromes (EXPLORE)

*Note - only open to Aplastic Anemia Patients

OPEN

BACK TO TOP
Prostate
SPONSOR/CROSTUDYSTATUS
RTOG 0517Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate.OPEN
SWOG 0421Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate CancerOPEN
RTOG 0534A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical ProstatectomyOPEN
TROPIC EFC 6193A Randomized, Open Label Multi-Center Study of XRP6258 at 25mg/m2 in Combination with Prednisone Every 3 weeks Compared to Mitoxantrone in Combination with Prednisone For the Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere-Containing RegimenOPEN

BACK TO TOP
Renal
SPONSOR/CROSTUDYSTATUS
GU 32

A Phase II Study of Bevacizumab Plus RAD001 in the Treatment of Patients with Metastatic Clear Cell Renal Cancer.

*Note - open to  patients with up to 1 previous systemic immunotherapy and/or chemotherapy regimen, who have also received treatment with either sorafenib or sunitinib.

OPEN
ECOG 2805A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell CarcinomaOPEN
GSK 012814Dosing and Switching Patterns, Efficacy, Safety, and Costs Associated with Angiogenesis Inhibitors in Patients with Metastatic Renal Cell Carcinoma: A Retrospective Medical Chart Review in The US Community Oncology SettingOPEN

BACK TO TOP
Esophagus
SPONSOR/CROSTUDYSTATUS
GI 91A Phase II Trial of Preoperative Concurrent Chemotherapy/ radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal CancerOPEN
RTOG 0436A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without SurgeryOPEN

BACK TO TOP
ITP
SPONSOR/CROSTUDYSTATUS

BACK TO TOP
Rectal
SPONSOR/CROSTUDYSTATUS
GI 65A Phase II Study of 5-Fluorouracil, Bevacizumab and Radiation Followed by Modified FOLFOX6 and Bevacizumab in the Adjuvant Treatment of Patients with Stage II/III Rectal Cancer  OPEN
ECOG 5204Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative ChemoradiationOPEN

BACK TO TOP
Unknown Primary
SPONSOR/CROSTUDYSTATUS

BACK TO TOP
ICON : Integrated Community Oncology Network